X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
ST101, a first-in-class antagonist of C/EBPβ, is currently being evaluated in the Phase 2 portion of an ongoing Phase 1-2 clinical study in patients with advanced unresectable and metastatic solid tumors.
Lead Product(s): ST101
Therapeutic Area: Oncology Product Name: ST101
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2022
Details:
The grant allows to further evaluate the efficacy of ST101 in patient-derived breast cancer models, which will inform patient selection criteria to enhance ST101's ability to treat multiple types of difficult cancers.
Lead Product(s): ST101
Therapeutic Area: Oncology Product Name: ST101
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: National Cancer Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding October 04, 2022
Details:
ST101 is peptide antagonist of C/EBPβ with dual MOA, antagonism of C/EBPβ promotes favorable immune tumor microenvironment by inhibiting formation of immunosuppressive myeloid-derived suppressor cells and cytotoxic activity in tumor cells.
Lead Product(s): ST101,Temozolomide
Therapeutic Area: Oncology Product Name: ST101
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2022
Details:
ST101 is showing promising results in GBM with a PR, which we have confirmed with repeat scans per mRANO and using an independent radiology reviewer.
Lead Product(s): ST101
Therapeutic Area: Oncology Product Name: ST101
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2022
Details:
ST101, a first-in-class antagonist of C/EBPβ, has demonstrated clinical proof-of-concept with a durable RECIST 1.1-confirmed partial response (PR) in a patient with cutaneous melanoma and evidence of long-lasting stable disease in several additional patients.
Lead Product(s): ST101
Therapeutic Area: Oncology Product Name: ST101
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 12, 2022
Details:
ST101, a first-in-class antagonist of C/EBPβ, is currently being evaluated in the Phase 2 portion of an ongoing Phase 1-2 clinical study in patients with advanced unresectable and metastatic solid tumors.
Lead Product(s): ST101
Therapeutic Area: Oncology Product Name: ST101
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2022
Details:
FDA has granted FTD to ST101 for the treatment of recurrent glioblastoma, currently being evaluated in an ongoing Phase 1-2 clinical study in patients with advanced unresectable and metastatic solid tumors.
Lead Product(s): ST101
Therapeutic Area: Oncology Product Name: ST101
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2021
Details:
ST101, a first-in-class peptide antagonist of C/EBPβ, will be investigated for its impact on primary and metastatic cancer and the tumor microenvironment, leveraging NCI's expertise in C/EBP biology and genetic mouse models
Lead Product(s): ST101
Therapeutic Area: Oncology Product Name: ST101
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: Sapience Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 27, 2021
Details:
First patient dossed in a Phase 1/2, open-label, dose escalation and expansion study of single agent ST101, a peptide therapy being evaluated for the treatment of adults with unresectable and metastatic solid tumors who are not eligible for other therapies.
Lead Product(s): ST101
Therapeutic Area: Oncology Product Name: ST101
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 12, 2020
Details:
U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for ST101, a peptide therapy being evaluated for the treatment of adults with unresectable and metastatic solid tumors.
Lead Product(s): ST101
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2020
Details:
MHRA UK has accepted Sapience's Clinical Trial Authorization application for ST101, a peptide therapy being evaluated for the treatment of adults with unresectable and metastatic solid tumors.
Lead Product(s): ST101
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 07, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
